Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 205

1.

Cannabis derivatives therapy for a seronegative stiff-person syndrome: a case report.

Vicente-Valor MI, Garcia-Llopis P, Mejia Andujar L, Antonino de la Camara G, García del Busto N, Lopez Tinoco MJ, Quintana Vergara B, Peiro Vilaplana C, Dominguez Moran JA, Sánchez Alcaraz A.

J Clin Pharm Ther. 2013 Feb;38(1):71-3. doi: 10.1111/j.1365-2710.2012.01365.x. Epub 2012 Jun 21.

PMID:
22726074
2.
3.

Advances in the management of multiple sclerosis spasticity: recent clinical trials.

Fernández O.

Eur Neurol. 2014;72 Suppl 1:9-11. doi: 10.1159/000367616. Epub 2014 Sep 26.

4.

THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.

Sastre-Garriga J, Vila C, Clissold S, Montalban X.

Expert Rev Neurother. 2011 May;11(5):627-37. doi: 10.1586/ern.11.47. Epub 2011 Apr 1. Review.

PMID:
21456949
5.

Focal stiff-person syndrome.

Fiol M, Cammarota A, Rivero A, Pardal A, Nogués M, Correale J.

Neurologia. 2001 Feb;16(2):89-91.

PMID:
11257937
6.

Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.

Haupts M, Vila C, Jonas A, Witte K, Álvarez-Ossorio L.

Eur Neurol. 2016;75(5-6):236-43. doi: 10.1159/000445943. Epub 2016 May 10.

PMID:
27160412
7.
9.

Stiff person syndrome.

Duddy ME, Baker MR.

Front Neurol Neurosci. 2009;26:147-65. doi: 10.1159/000212375. Epub 2009 Apr 6. Review.

PMID:
19349711
10.

Trialing of intrathecal baclofen therapy for refractory stiff-person syndrome.

Newton JC, Harned ME, Sloan PA, Salles SS.

Reg Anesth Pain Med. 2013 May-Jun;38(3):248-50. doi: 10.1097/AAP.0b013e318288b8f9.

PMID:
23518865
11.

THC:CBD spray and MS spasticity symptoms: data from latest studies.

Rekand T.

Eur Neurol. 2014;71 Suppl 1:4-9. doi: 10.1159/000357742. Epub 2014 Jan 22. Review.

12.

Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex®): A Review in Multiple Sclerosis-Related Spasticity.

Keating GM.

Drugs. 2017 Apr;77(5):563-574. doi: 10.1007/s40265-017-0720-6. Review.

PMID:
28293911
13.

Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity.

Koehler J, Feneberg W, Meier M, Pöllmann W.

Int J Neurosci. 2014 Sep;124(9):652-6. doi: 10.3109/00207454.2013.877460. Epub 2014 Jan 23.

PMID:
24392812
14.

Clinical case reviews and poster sessions in multiple sclerosis spasticity: main outcomes and highlights.

Trojano M, Celius EG, Donzé C, Izquierdo G, Patti F, Pöhlau D.

Eur Neurol. 2014;72 Suppl 1:15-9. doi: 10.1159/000367619. Epub 2014 Sep 26.

15.

Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.

Syed YY, McKeage K, Scott LJ.

Drugs. 2014 Apr;74(5):563-78. doi: 10.1007/s40265-014-0197-5. Review.

PMID:
24671907
16.

The stiff-person syndrome. Case report.

Piovano C, Piattelli M, Spina T, Iervese G, Bosco G.

Minerva Anestesiol. 2002 Nov;68(11):861-5.

17.

The detection of THC, CBD and CBN in the oral fluid of Sativex® patients using two on-site screening tests and LC-MS/MS.

Molnar A, Fu S, Lewis J, Allsop DJ, Copeland J.

Forensic Sci Int. 2014 May;238:113-9. doi: 10.1016/j.forsciint.2014.03.004. Epub 2014 Mar 12.

PMID:
24699310
18.

Cannabis; adverse effects from an oromucosal spray.

Scully C.

Br Dent J. 2007 Sep 22;203(6):E12; discussion 336-7. Epub 2007 Aug 17.

PMID:
17703180
19.

The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity.

Celius EG, Vila C.

Brain Behav. 2018 Apr 6;8(5):e00962. doi: 10.1002/brb3.962. eCollection 2018 May.

20.

Intrathecal baclofen pump implantation in a case of stiff person syndrome.

Maramattom BV.

Neurol India. 2010 Jan-Feb;58(1):115-7. doi: 10.4103/0028-3886.60420.

Supplemental Content

Support Center